How to buy ThermoGenesis stock | $2.85

ThermoGenesis Holdings, Inc is a medical devices business based in the US. ThermoGenesis shares (THMO) are listed on the NASDAQ and all prices are listed in US Dollars. ThermoGenesis employs 40 staff and has a trailing 12-month revenue of around 0.00.

ThermoGenesis stock price (NASDAQ: THMO)

Use our graph to track the performance of THMO stocks over time.

ThermoGenesis shares at a glance

• Key figures

Information last updated 2021-07-31.

Latest market close	$2.85
52-week range	$1.92 - $6.45
50-day moving average	$2.57
200-day moving average	$2.73
Wall St. target price	$6.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-3.29

Buy ThermoGenesis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy ThermoGenesis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of ThermoGenesis Holdings, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ThermoGenesis price performance over time

Historical closes compared with the close of $2.85 from 2021-06-08

1 week (2021-07-22)	N/A
1 month (2021-07-02)	7.95%
3 months (2021-04-30)	1.42%
6 months (2021-01-29)	N/A

1 year (2020-07-29)	N/A
2 years (2019-07-29)	N/A
3 years (2018-07-29)	N/A
5 years (2016-07-29)	N/A

ThermoGenesis financials

Revenue TTM	$8.1 million
Gross profit TTM	$1.3 million
Return on assets TTM	-27.83%
Return on equity TTM	-194.2%
Profit margin	-175.69%
Book value	$0.88
Market capitalisation	$27.5 million

TTM: trailing 12 months

Shorting ThermoGenesis shares

There are currently 319,008 ThermoGenesis shares held short by investors – that's known as ThermoGenesis's "short interest". This figure is 22.2% down from 410,138 last month.

There are a few different ways that this level of interest in shorting ThermoGenesis shares can be evaluated.

ThermoGenesis's "short interest ratio" (SIR)

ThermoGenesis's "short interest ratio" (SIR) is the quantity of ThermoGenesis shares currently shorted divided by the average quantity of ThermoGenesis shares traded daily (recently around 292667.88990826). ThermoGenesis's SIR currently stands at 1.09. In other words for every 100,000 ThermoGenesis shares traded daily on the market, roughly 1090 shares are currently held short.

However ThermoGenesis's short interest can also be evaluated against the total number of ThermoGenesis shares, or, against the total number of tradable ThermoGenesis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ThermoGenesis's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 ThermoGenesis shares in existence, roughly 30 shares are currently held short) or 0.0335% of the tradable shares (for every 100,000 tradable ThermoGenesis shares, roughly 34 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ThermoGenesis.

Find out more about how you can short ThermoGenesis stock.

ThermoGenesis share dividends

We're not expecting ThermoGenesis to pay a dividend over the next 12 months.

Have ThermoGenesis's shares ever split?

ThermoGenesis's shares were split on a 1:10 basis on 4 June 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ThermoGenesis shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for ThermoGenesis shares which in turn could have impacted ThermoGenesis's share price.

ThermoGenesis share price volatility

Over the last 12 months, ThermoGenesis's shares have ranged in value from as little as $1.92 up to $6.45. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ThermoGenesis's is 3.3281. This would suggest that ThermoGenesis's shares are significantly more volatile than the average for this exchange and represent a higher risk.

ThermoGenesis overview

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP II Automated Cell Separation System, an automated cell separation system for isolating and retrieving stem, and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc.

Frequently asked questions

What percentage of ThermoGenesis is owned by insiders or institutions?
Currently 25.05% of ThermoGenesis shares are held by insiders and 3.354% by institutions. How many people work for ThermoGenesis?
Latest data suggests 40 work at ThermoGenesis. When does the fiscal year end for ThermoGenesis?
ThermoGenesis's fiscal year ends in December. Where is ThermoGenesis based?
ThermoGenesis's address is: 2711 Citrus Road, Rancho Cordova, CA, United States, 95742 What is ThermoGenesis's ISIN number?
ThermoGenesis's international securities identification number is: US88362L1008 What is ThermoGenesis's CUSIP number?
ThermoGenesis's Committee on Uniform Securities Identification Procedures number is: 157131103